Kura Oncology Inc. anticipates achieving key milestones such as successful patient enrollment, interim efficacy results, safety profile assessments, and potential regulatory submissions for ziftomenib in newly diagnosed AML patients during the KOMET-017-IC and NIC Phase 3 studies.